In antihyperglycaemic medication, the MTM group was more commonly treated with insulin (6.8% vs. 4.6%), metformin (33.7% vs. 29.6%) and less frequently with dipeptidyl peptidase 4 (DPP-4) inhibitors (7.6% vs. 13.2%) compared to the control group, which is more closely aligned with the medication recommendations of the American Diabetes Association guidelines. This evidence concerns the gene DPP4 and diabetes mellitus.